Daniel Bexell
Overview
Explore the profile of Daniel Bexell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karlsson J, Yasui H, Manas A, Andersson N, Hansson K, Aaltonen K, et al.
Nat Commun
. 2024 Oct;
15(1):8992.
PMID: 39419962
Neuroblastoma (NB) is one of the most lethal childhood cancers due to its propensity to become treatment resistant. By spatial mapping of subclone geographies before and after chemotherapy across 89...
2.
Gunnarsdottir F, Briem O, Lindgren A, Kallberg E, Andersen C, Grenthe R, et al.
Front Immunol
. 2023 Jul;
14:1180209.
PMID: 37404831
CD169 resident macrophages in lymph nodes of breast cancer patients are for unknown reasons associated with a beneficial prognosis. This contrasts CD169 macrophages present in primary breast tumors (CD169 TAMs),...
3.
Valind A, Verhoeven B, Enoksson J, Karlsson J, Christensson G, Manas A, et al.
Oncoimmunology
. 2023 Mar;
12(1):2184130.
PMID: 36875552
Despite aggressive treatment, the 5-year event-free survival rate for children with high-risk neuroblastoma is <50%. While most high-risk neuroblastoma patients initially respond to treatment, often with complete clinical remission, many...
4.
Aaltonen K, Radke K, Adamska A, Seger A, Manas A, Bexell D
Front Oncol
. 2023 Feb;
12:1085270.
PMID: 36776363
Neuroblastoma is a childhood cancer derived from the sympathetic nervous system. High-risk neuroblastoma patients have a poor overall survival and account for ~15% of childhood cancer deaths. There is thus...
5.
Manas A, Aaltonen K, Andersson N, Hansson K, Adamska A, Seger A, et al.
Sci Adv
. 2022 Oct;
8(43):eabq4617.
PMID: 36306349
Chemotherapy resistance and relapses are common in high-risk neuroblastoma (NB). Here, we developed a clinically relevant in vivo treatment protocol mimicking the first-line five-chemotherapy treatment regimen of high-risk NB and...
6.
Grigoryan A, Zacharaki D, Balhuizen A, Come C, Garcia Garcia A, Hidalgo Gil D, et al.
Sci Transl Med
. 2022 Oct;
14(666):eabm6391.
PMID: 36223446
The bone marrow microenvironment provides indispensable factors to sustain blood production throughout life. It is also a hotspot for the progression of hematologic disorders and the most frequent site of...
7.
Olm F, Panse L, Dykes J, Bexell D, Laurell T, Scheding S
Stem Cell Res Ther
. 2021 Oct;
12(1):542.
PMID: 34654486
Background: Graft-contaminating tumor cells correlate with inferior outcome in high-risk neuroblastoma patients undergoing hematopoietic stem cell transplantation and can contribute to relapse. Motivated by the potential therapeutic benefit of tumor...
8.
Radke K, Hansson K, Sjolund J, Wolska M, Karlsson J, Esfandyari J, et al.
Transl Oncol
. 2021 Jun;
14(8):101149.
PMID: 34118691
High-risk neuroblastoma has a poor prognosis despite intense treatment, demonstrating the need for new therapeutic strategies. Here we evaluated the effects of rigosertib (ON-01910.Na) in preclinical models of high-risk neuroblastoma....
9.
Ruiz-Perez M, Sainero-Alcolado L, Oliynyk G, Matuschek I, Balboni N, Ubhayasekera S, et al.
iScience
. 2021 Mar;
24(2):102128.
PMID: 33659885
Many metabolic pathways, including lipid metabolism, are rewired in tumors to support energy and biomass production and to allow adaptation to stressful environments. Neuroblastoma is the second deadliest solid tumor...
10.
Hansson K, Radke K, Aaltonen K, Saarela J, Manas A, Sjolund J, et al.
Sci Transl Med
. 2020 Sep;
12(562).
PMID: 32967973
Neuroblastoma is a childhood malignancy with often dismal prognosis; relapse is common despite intense treatment. Here, we used human tumor organoids representing multiple -amplified high-risk neuroblastomas to perform a high-throughput...